Cargando…

The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy

BACKGROUND: Immune checkpoint blockades (ICBs) are characterized by a durable clinical response and better tolerability in patients with a variety of advanced solid tumors. However, we not infrequently encounter patients with hyperprogressive disease (HPD) exhibiting paradoxically accelerated tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Seo Ree, Chun, Sang Hoon, Kim, Joo Ri, Kim, Sang-Yeob, Seo, Jun Young, Jung, Chan Kwon, Gil, Bo-Mi, Kim, Jeong-Oh, Ko, Yoon Ho, Woo, In Sook, Shim, Byoung Yong, Hong, Sook-Hee, Kang, Jin Hyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786505/ https://www.ncbi.nlm.nih.gov/pubmed/33402127 http://dx.doi.org/10.1186/s12885-020-07727-y

Ejemplares similares

Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019)

Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019)

Prediction model for hyperprogressive disease in non‐small cell lung cancer treated with immune checkpoint inhibitors
por: Choi, Yong Jun, et al.
Publicado: (2020)

Clinical experience of immune checkpoint inhibitor for a metastatic jejunal cancer patient with a high tumor mutational burden and low expression of programmed death-ligand 1
por: Kim, Seo Ree, et al.
Publicado: (2020)

Hyperprogression after Immunotherapy: Nivolumab. Analysis of Imaging Findings Associated with Hyperprogression and Tumor Growth Kinetics
por: Singla, Rishu, et al.
Publicado: (2021)

Unravelling the underpinnings of hyperprogression and immunotherapy: back to the bench
por: Subbiah, Vivek, et al.
Publicado: (2022)

Is hyperprogressive disease a specific phenomenom of immunotherapy?
por: Brambilla, Marta, et al.
Publicado: (2020)

Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?
por: Adashek, Jacob J., et al.
Publicado: (2020)

Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
por: Wei, Zhanqi, et al.
Publicado: (2022)

Hyperprogression: A novel response pattern under immunotherapy
por: Han, Xue‐jiao, et al.
Publicado: (2020)

CAR T Cell Immunotherapy Beyond Haematological Malignancy
por: Hupperetz, Cedric, et al.
Publicado: (2022)

Hyperprogression after immunotherapy in patients with malignant tumors of digestive system
por: Ji, Zhi, et al.
Publicado: (2019)

Hyperprogression of Liver Metastasis With Neoadjuvant Immunotherapy for Soft Tissue Sarcoma
por: Chan, Abigail S, et al.
Publicado: (2020)

Hyperprogression: A Unique Phenomenon of Progression of Existing Tumor Secondary to Immunotherapy
por: Mandal, Shobha, et al.
Publicado: (2021)

Hyperprogression After Immunotherapy for Primary Small Cell Neuroendocrine Carcinoma of the Ureter: A Case Report
por: Qing, Defeng, et al.
Publicado: (2021)

Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review
por: Lin, Miaozhen, et al.
Publicado: (2021)

Hyperprogressive Disease After Immunotherapy: A Case Report of Pulmonary Enteric Adenocarcinoma
por: Hu, Chun-Hong, et al.
Publicado: (2022)

Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
por: Gong, Caifeng, et al.
Publicado: (2023)

Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
por: Lee, Dong Min, et al.
Publicado: (2017)

Clinical outcomes of hyperprogression based on volumetry in non‐small cell lung cancer after immune checkpoint inhibitor treatment
por: Kim, Jehun, et al.
Publicado: (2022)

Tagmentation-based analysis reveals the clonal behavior of CAR-T cells in association with lentivector integration sites
por: Kim, Jaeryuk, et al.
Publicado: (2023)

Immunogenomic Landscape Contributes to Hyperprogressive Disease after Anti-PD-1 Immunotherapy for Cancer
por: Xiong, Donghai, et al.
Publicado: (2018)

Evaluation of Two EGFR Mutation Tests on Tumor and Plasma from Patients with Non-Small Cell Lung Cancer
por: Kim, Jeong-Oh, et al.
Publicado: (2020)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
por: Bennani, N Nora, et al.
Publicado: (2022)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

MicroRNA-769-3p Acts as a Prognostic Factor in Oral Squamous Cell Cancer by Modulating Stromal Genes
por: Lee, Heejin, et al.
Publicado: (2022)

Iodine-125 radioactive particles antagonize hyperprogressive disease following immunotherapy: A case report
por: Yang, Ning, et al.
Publicado: (2020)

Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
por: Kim, Seo Ree, et al.
Publicado: (2020)

Hyperprogressive Disease In a Metastatic Renal Cell Carcinoma Patient After Receiving Immune Checkpoint Inhibitors: A Case Report
por: Alkader, Mohammad, et al.
Publicado: (2022)

A Rare Complication of a Large Emphysema after Orbital Wall Fracture Surgery with Silastic Sheet Implant
por: Park, Ella SeoYeon, et al.
Publicado: (2020)

Disease progression modeling of Alzheimer’s disease according to education level
por: Kim, Ko Woon, et al.
Publicado: (2020)

CD11c(+) Cells Partially Mediate the Renoprotective Effect Induced by Bone Marrow-Derived Mesenchymal Stem Cells
por: Kim, Myung-Gyu, et al.
Publicado: (2013)

Efficacy of concurrent chemoradiotherapy for patients with limited-disease small-cell lung cancer: a retrospective, nationwide, population-based cohort study
por: Kim, Seo Ree, et al.
Publicado: (2021)

Hyperprogressive Disease (HPD) in Solid Tumours Receiving Immune Checkpoint Inhibitors in a Real-World Setting
por: Kanjanapan, Yada, et al.
Publicado: (2023)

Prognostic value of Dickkopf-1 and ß-catenin expression according to the antitumor immunity of CD8-positive tumor-infiltrating lymphocytes in biliary tract cancer
por: Kim, Seo Ree, et al.
Publicado: (2022)

Identification and Characterization of Cancer-Associated Fibroblast Subpopulations in Lung Adenocarcinoma
por: Kim, Daeseung, et al.
Publicado: (2022)

The Effects of Transglutaminase and Refrigerated Storage on the Physicochemical Properties of Whole Wheat Dough and Noodles
por: Kang, Min Jeong, et al.
Publicado: (2021)

Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma
por: Sun, Dantong, et al.
Publicado: (2020)

Hyperprogression of a spindle‐cell squamous carcinoma of the esophagus after esophagectomy
por: Ji, Yanli, et al.
Publicado: (2022)

Hyperprogression of cutaneous T cell lymphoma after anti–PD-1 treatment
por: Gao, Yumei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fvf6p3kuhf27n509u854smoe7c